



Xcelience, LLC
5415 West Laurel Street
Tampa, FL 33607
Phone: 813-286-0404
Fax: 813-286-1105
Website: www.xcelience.com
E-mail: Randall.Guthrie@xcelience.com

Xcelience Expands Its Early Drug Development Capabilities

Xcelience, a leading pharmaceutical contract research organization, is the premier source for unsurpassed quality in drug development. We consistently and efficiently move our sponsors' Active Pharmaceutical Ingredients (APIs) through the drug formulation process, getting them to clinic and market faster. Xcelience combines the industry's top-performing formulation development scientists with state-of-the-art equipment.

Led by dedicated project management, our scientific teams work as an extension of your organization throughout the drug development process.

Xcelience's Core Services

Preformulation:

Xcelience's range of preformulation studies allows us to optimize your dosage form at the earliest stage of drug development. Our scientists have experience in the preformulation to support all your product needs.

Formulation:

The scientific team creates options for formulation to meet your dosage range and preferred route of delivery. We are able to formulate the following dosage forms:

- **Solids**
 - Tablet formulation
 - Hard gelatin capsule formulation
 - Granules
 - Powders
- **Liquids:**
 - Oral and topical liquids
 - Suspensions
 - Emulsions
- **Semi-solids:**
 - Creams
 - Ointments
 - Gels

Analytical:

State-of-the-art facilities and instrumentation provide an optimal environment for stability studies, including a full range of temperature and relative-humidity conditions.

Manufacturing:

Our scientists are the industry's most respected in the field of formulation development. Contact us for:

- Manufacturing batches for stability testing
- Scaling up and production of pilot batches
- Manufacturing of clinical trials supplies from Phase I to Phase IIb, including individual capsule filling of API, tableting, encapsulation, placebo matching, over-encapsulation or coating of comparators.
- Process validation and technology transfer.

Xcelience has expanded our early drug development capabilities by being the first CRO in North America to acquire the Xcelodose® 600 S precision powder micro-doser and automated encapsulator system. The next generation S model fills at speeds of over 600 capsules an hour, and accompanies its predecessor the Xcelodose 600 in our effort to get sponsors to clinic.

Xcelience has built up a wealth of drug development experience since purchasing its first Xcelodose system in 2005. Sponsors are drawn to the company's speed in helping get them to the clinic. The new model is faster and will add to our responsiveness time.

Xcelodose® is a registered trademark of Capsugel BVBA.

Facility Overview:

Xcelience has grown exponentially since its inception. In addition to expanding operations in 2007 with the acquisition of a new facility, the company boasts an array of new equipment, including the Vector TFC Roll Compactor, to further amplify its vast capabilities. Our laboratories are fully cGMP compliant and registered with the FDA and DEA.

*We Challenge You to Challenge Us
Xcelience®
Xcelling the Science of Formulation Development*